Citius Oncology, Inc. Common Stock (CTOR) is a publicly traded Healthcare sector company. As of May 21, 2026, CTOR trades at $0.81 with a market cap of $77.07M and a P/E ratio of -2.37. CTOR moved -4.61% today. Year to date, CTOR is -28.17%; over the trailing twelve months it is -7.19%. Its 52-week range spans $0.49 to $6.19. Analyst consensus is buy with an average price target of $6.00. Rallies surfaces CTOR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes CTOR SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $0.81 |
| Market Cap | $77.07M |
| P/E Ratio | -2.37 |
| EPS | $-0.34 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.19 |
| 52-Week Low | $0.49 |
| Volume | 521 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-24.76M |
| Gross Margin | 0.00% |
1 analysts cover CTOR: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.00.